Natural News
Tuesday, February 15, 2011 by: Rosemary Mathis, Director of SANE VAX, INC.
Written by Norma Erickson
In a letter addressed to Dr. Margaret Hamburg, the FDA commissioner, Ms. Norma Erickson, president of S.A.N.E. Vax, Inc. stated her research team has revealed that in November 2001 the VRBPAC (Vaccines and Related Biological Products Advisory Committee) mistakenly allowed the vaccine manufacturer to use “CIN 2/3, AIS, or cervical cancer; i.e. CIN 2/3 or worse by histology – with virology to determine the associated HPV type – as the primary endpoint in the evaluation of a vaccine to prevent cervical cancer.”